Serum markers of immune activation in HIV-associated pulmonary tuberculosis.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Serum markers of immune activation in HIV-associated pulmonary tuberculosis.

Abstr Gen Meet Am Soc Microbiol. 1994;94:190 (abstract no. U-99). Unique Identifier : AIDSLINE ASM94/94313075
Wallis R; Helfand M; Vjecha M; Whalen C; Mugerwa R; Okwera A; Ellner J; Case Western Reserve University, Cleveland, Ohio.

Abstract: Survival is shortened in HIV-infected patients with tuberculosis (TB) as compared to CD4-matched HIV-infected controls. We measured serum markers of immune activation in HIV-infected patients beginning treatment for pulmonary TB in Kampala, Uganda. Patients were followed for 16 months or until death. Initial levels of neopterin, beta 2 microglobulin, and receptors to TNF alpha and IL-2 were significantly higher in those who died: TABULAR DATA, SEE ABSTRACT VOLUME. These parameters did not correlate with X-ray findings as to extent location, or cavitary nature of disease. The markers did not change significantly during the first 2 months of therapy in either survivors or non-survivors, not did they predict radiographic or microbiologic response to therapy or relapse. This suggests that mortality in HIV-associated tuberculosis may be more closely related to stage and/or progression of HIV disease rather than to progressive tuberculosis. Inasmuch as serum levels of receptors for IL-2 and TNF alpha parallel production of these cytokines in vivo, and both cytokines promote HIV expression in vitro, increased production of cytokines may provide mechanism for acceleration of HIV disease in patients with tuberculosis.

Keywords: AIDS-Related Opportunistic Infections/*BLOOD/IMMUNOLOGY/MORTALITY Biological Markers/BLOOD Biopterin/*ANALOGS & DERIVATIVES/BLOOD Comparative Study Human Predictive Value of Tests Prognosis Receptors, Interleukin-2/*ANALYSIS Receptors, Tumor Necrosis Factor/*ANALYSIS Survival Rate Tuberculosis, Pulmonary/*BLOOD/COMPLICATIONS/MORTALITY ABSTRACT
941030
M94A0879

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .